Physician profile
Shantha Murthy
NPI 1427080803
$2,538.04
in general payments reported to CMS, 2019-2025
18 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $323 · 2021: $395 · 2022: $318 · 2023: $131 · 2024: $512 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $453 · Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $452.65 |
| Food and Beverage | $439.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $714.08 | 2019-2025 | Dovato |
| Gilead Sciences, INC. | $483.02 | 2019-2025 | Biktarvy |
| Baxter Healthcare | $452.65 | 2024 | Hillrom - Spot Vision Screener |
| Merck Sharp & Dohme LLC | $156.38 | 2020-2024 | Verquvo, Belsomra, Delstrigo |
| E.R. Squibb & Sons, L.L.C. | $145.43 | 2022-2025 | Eliquis |
| Janssen Products, Lp | $139.98 | 2019-2021 | |
| Pfizer INC. | $92.99 | 2020-2022 | |
| Novo Nordisk INC | $88.83 | 2022-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $60.62 | 2020-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $55.68 | 2020-2021 | |
| Janssen Biotech, INC. | $33.66 | 2021 | |
| Sk Life Science, INC. | $23.18 | 2025 | |
| Abbvie INC. | $19.90 | 2022 | |
| Horizon Therapeutics Plc | $16.27 | 2020 | |
| Glaxosmithkline, LLC. | $15.56 | 2023 | Boostrix, Shingrix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.13 | 2021 | |
| Mission Pharmacal Company | $13.67 | 2019 | |
| Shield Therapeutics INC | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shantha Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.